Blockchain Registration Transaction Record

Quantum BioPharma Partners with Thermo Fisher for Lucid-MS Phase 2 Trial

Quantum BioPharma partners with Thermo Fisher to launch Phase 2 trial of Lucid-MS for multiple sclerosis, a first-in-class neuroprotective treatment targeting PAD2.

This news matters because it marks a critical step forward in the development of a potential first-in-class treatment for multiple sclerosis, a chronic and often debilitating disease affecting millions worldwide. The collaboration with Thermo Fisher's PPD Clinical Research Business brings significant clinical trial expertise to the table, which could accelerate the timeline for bringing Lucid-MS to market. If successful, Lucid-MS could offer a new mechanism of action by targeting PAD2 to inhibit demyelination, potentially providing neuroprotection for patients with progressive forms of MS who currently have limited treatment options. For investors, this agreement signals progress and validates the company's approach, potentially impacting Quantum BioPharma's stock value and future partnerships.